Moderate Evidence
Research Overview
Oveporexton Research for Excessive Daytime Sleepiness
An evidence-based overview of research examining Oveporexton in the context of excessive daytime sleepiness. This page synthesizes findings from peer-reviewed literature.
Research Summary
Primary endpoint of ORCHESTRA-NT1 showed significant ESS reduction. Oveporexton promotes wakefulness through direct OX2R activation in arousal centers, addressing the underlying orexin deficiency.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Oveporexton may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.